125 related articles for article (PubMed ID: 10845932)
1. Differential expression of a novel C-terminally truncated splice form of SMAD5 in hematopoietic stem cells and leukemia.
Jiang Y; Liang H; Guo W; Kottickal LV; Nagarajan L
Blood; 2000 Jun; 95(12):3945-50. PubMed ID: 10845932
[TBL] [Abstract][Full Text] [Related]
2. Smad5, a tumor suppressor candidate at 5q31.1, is hemizygously lost and not mutated in the retained allele in human leukemia cell line HL60.
Zavadil J; Brezinová J; Svoboda P; Zemanová Z; Michalová K
Leukemia; 1997 Aug; 11(8):1187-92. PubMed ID: 9264367
[TBL] [Abstract][Full Text] [Related]
3. Localization of SMAD5 and its evaluation as a candidate myeloid tumor suppressor.
Hejlik DP; Kottickal LV; Liang H; Fairman J; Davis T; Janecki T; Sexton D; Perry W; Tavtigian SV; Teng DH; Nagarajan L
Cancer Res; 1997 Sep; 57(17):3779-83. PubMed ID: 9288787
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Smad5 in human hematopoietic progenitors blocks erythroid differentiation induced by BMP4.
Fuchs O; Simakova O; Klener P; Cmejlova J; Zivny J; Zavadil J; Stopka T
Blood Cells Mol Dis; 2002; 28(2):221-33. PubMed ID: 12064918
[TBL] [Abstract][Full Text] [Related]
5. An antisense transcript to SMAD5 expressed in fetal and tumor tissues.
Zavadil J; Svoboda P; Liang H; Kottickal LV; Nagarajan L
Biochem Biophys Res Commun; 1999 Feb; 255(3):668-72. PubMed ID: 10049768
[TBL] [Abstract][Full Text] [Related]
6. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis.
Bruno E; Horrigan SK; Van Den Berg D; Rozler E; Fitting PR; Moss ST; Westbrook C; Hoffman R
Blood; 1998 Mar; 91(6):1917-23. PubMed ID: 9490674
[TBL] [Abstract][Full Text] [Related]
7. Characterization of zebrafish smad1, smad2 and smad5: the amino-terminus of smad1 and smad5 is required for specific function in the embryo.
Müller F; Blader P; Rastegar S; Fischer N; Knöchel W; Strähle U
Mech Dev; 1999 Oct; 88(1):73-88. PubMed ID: 10525190
[TBL] [Abstract][Full Text] [Related]
8. SMAD5 gene expression, rearrangements, copy number, and amplification at fragile site FRA5C in human hepatocellular carcinoma.
Zimonjic DB; Durkin ME; Keck-Waggoner CL; Park SW; Thorgeirsson SS; Popescu NC
Neoplasia; 2003; 5(5):390-6. PubMed ID: 14670176
[TBL] [Abstract][Full Text] [Related]
9. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12.
Nishimura R; Kato Y; Chen D; Harris SE; Mundy GR; Yoneda T
J Biol Chem; 1998 Jan; 273(4):1872-9. PubMed ID: 9442019
[TBL] [Abstract][Full Text] [Related]
10. Smad1 and smad5 act downstream of intracellular signalings of BMP-2 that inhibits myogenic differentiation and induces osteoblast differentiation in C2C12 myoblasts.
Yamamoto N; Akiyama S; Katagiri T; Namiki M; Kurokawa T; Suda T
Biochem Biophys Res Commun; 1997 Sep; 238(2):574-80. PubMed ID: 9299554
[TBL] [Abstract][Full Text] [Related]
11. Roles for the MH2 domain of Smad7 in the specific inhibition of transforming growth factor-beta superfamily signaling.
Mochizuki T; Miyazaki H; Hara T; Furuya T; Imamura T; Watabe T; Miyazono K
J Biol Chem; 2004 Jul; 279(30):31568-74. PubMed ID: 15148321
[TBL] [Abstract][Full Text] [Related]
12. Expression of Smad proteins in human colorectal cancer.
Korchynskyi O; Landström M; Stoika R; Funa K; Heldin CH; ten Dijke P; Souchelnytskyi S
Int J Cancer; 1999 Jul; 82(2):197-202. PubMed ID: 10389752
[TBL] [Abstract][Full Text] [Related]
13. Disruption of Smad5 gene leads to enhanced proliferation of high-proliferative potential precursors during embryonic hematopoiesis.
Liu B; Sun Y; Jiang F; Zhang S; Wu Y; Lan Y; Yang X; Mao N
Blood; 2003 Jan; 101(1):124-33. PubMed ID: 12393578
[TBL] [Abstract][Full Text] [Related]
14. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31.
Horrigan SK; Arbieva ZH; Xie HY; Kravarusic J; Fulton NC; Naik H; Le TT; Westbrook CA
Blood; 2000 Apr; 95(7):2372-7. PubMed ID: 10733509
[TBL] [Abstract][Full Text] [Related]
15. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis.
Imai Y; Kurokawa M; Izutsu K; Hangaishi A; Maki K; Ogawa S; Chiba S; Mitani K; Hirai H
Oncogene; 2001 Jan; 20(1):88-96. PubMed ID: 11244507
[TBL] [Abstract][Full Text] [Related]
16. Expression of functional Schistosoma mansoni Smad4: role in Erk-mediated transforming growth factor beta (TGF-beta) down-regulation.
Osman A; Niles EG; LoVerde PT
J Biol Chem; 2004 Feb; 279(8):6474-86. PubMed ID: 14630909
[TBL] [Abstract][Full Text] [Related]
17. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13).
Yagasaki F; Jinnai I; Yoshida S; Yokoyama Y; Matsuda A; Kusumoto S; Kobayashi H; Terasaki H; Ohyashiki K; Asou N; Murohashi I; Bessho M; Hirashima K
Genes Chromosomes Cancer; 1999 Nov; 26(3):192-202. PubMed ID: 10502316
[TBL] [Abstract][Full Text] [Related]
18. The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation.
Lindberg SR; Olsson A; Persson AM; Olsson I
Exp Hematol; 2005 Feb; 33(2):189-98. PubMed ID: 15676213
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
Kuang C; Chen Y
Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the DNA-binding property of Smad5.
Li W; Chen F; Nagarajan RP; Liu X; Chen Y
Biochem Biophys Res Commun; 2001 Sep; 286(5):1163-9. PubMed ID: 11527422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
